Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

NCT03462446 · clinicaltrials.gov ↗

COMPLETED

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Vitamin K antagonists (VKAs)

Sponsor

Bayer

Collaborators

[object Object]